The Royal Melbourne Hospital (RMH), located in Parkville, Victoria, an inner suburb of Melbourne, is one of Australia's leading public hospitals. It is a major teaching hospital for tertiary health care with a reputation in clinical research. The hospital is managed as part of Melbourne Health which comprises the Royal Melbourne Hospital, North West Dialysis Service and North Western Mental Health. The Melbourne Health Chief Executive is Christine Kilpatrick AO.The emergency department is at the City Campus, 300 Grattan Street, Parkville.
Renal imaging suggests that congenital anomalies of the kidney and urinary tract (CAKUT) affect one in 200 of the population, and 20
Foslevodopa/foscarbidopa (LDp/CDp) is a nonsurgical 24-h continuous subcutaneous infusion for patients with advanced Parkinson’s disease (aPD) and motor fluctuations uncontrolled on oral medications. We present the first multicountry real-world data from routine clinical practice. ROSSINI (NCT06107426) is an ongoing 3-year multicountry, prospective, observational study of adults with aPD who are LDp/CDp-naïve (cohort A) or transitioning from LDp/CDp open-label extension studies (NCT04379050/NCT04750226, cohort B). For this interim analysis, the primary endpoint was change from baseline to 6 months in OFF time [Movement Disorder Society Unified Parkinson’s Disease Rating Scale Part IV (MDS-UPDRS-IV) modified item 4.3]. Safety was assessed by monitoring adverse events (AEs). Interim results for 105 cohort A patients enrolled ≥ 6 months by March 24, 2025 are presented only; cohort B results were limited (n = 5). Mixed-effects models for repeated measurements (continuous outcomes) were utilized, adjusted for country. Cohort A patients had a mean (SD) age of 68.5 (9.5) years, PD duration of 12.1 (5.3) years, and least squares mean (SE) OFF time of 5.2 (0.6) h at baseline. Patients on LDp/CDp showed statistically significant reductions (95
A myriad of pathological process may involve the pituitary stalk (infundibulum), and despite extensive investigations, biopsy is often required. Due to the rarity of the procedure, the risks and yield of stalk biopsy are not well known, with important implications for clinical decision making. A systematic review was performed in accordance with the PRISMA statement. Studies that reported diagnostic yield and complication rates after stalk biopsy were included. Bias was assessed using ROBINS-V2. A total of 13 studies, including 832 patients and 406 biopsies were included. Mean time from diagnosis to biopsy was 11 months. Preoperative visual symptoms were seen in 29.1
Leukocyte count is widely available and included in Intensive Care Unit prognostic systems. We hypothesised that the relationship between leukocytosis and mortality risk might differ in critically ill patients admitted with infection, where leukocytosis may be an adaptive response. We performed a registry-based study using the Australian and New Zealand Intensive Care Society Adult Patient Database between 2010 and 2023, across 212 Intensive Care Units. Using descriptive statistics and mixed-effects multivariable logistic regression, we evaluated the association between early peak leukocyte count and mortality, according to whether infection was the primary diagnosis. We examined 2,016,578 patients, of whom 1,742,195 had non-infective illnesses (86.4
Research on acute kidney injury (AKI) is hindered by heterogeneous definitions, measurements, and follow-up periods, which limit comparability across randomized controlled trials (RCTs) and the translation of findings into evidence-based practice. This review aimed to describe outcomes reported in RCTs of AKI prevention and treatment. This scoping review followed PRISMA-ScR guidance. PubMed, Embase, Web of Science, and Cochrane CENTRAL were searched for RCTs published between January 2014 and April 2024. Eligible studies included adults or children with AKI or at risk for AKI. Outcomes were categorized using the COMET taxonomy according to core area, core domain, specific domain, measurement method, and timing. Among 3921 abstracts screened, 251 RCTs were included. Prevention trials represented 197/251 (78.5
